Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

18.12.13	Merck Collaborates With GSK To Evaluate Novel Combination Regimen For Adv RCC (RTTNews)
17.12.13	MSD Animal Health Gets Positive Opinion From CVMP In Europe For Bravecto (RTTNews)
13.12.13	FDA Panel Recommends Approval Of Merck's Allergy Drug Grastek (RTTNews)
03.12.13	ACRX At FDA Altar, Orphan Drug Status Lifts CNAT, LCI Moves To NYSE (RTTNews)
02.12.13	Forest Laboratories To Buy Exclusive Rights For Saphris From Merck Sharp & Dohme (RTTNews)
26.11.13	Merck Gets FDA Approval For Noxafil Delayed-Release Tablets - Quick Facts (RTTNews)
18.11.13	Merck's NDA For IV Formulation Of Noxafil Obtains FDA Priority Review (RTTNews)
15.11.13	Akorn Buys Three Branded Ophthalmic Products From Merck For $52.8 Mln In Cash (RTTNews)
15.11.13	Merck Invests 80 Mln Euros In Pharma Manufacturing Facility In China (RTTNews)
09.11.13	Merck Reports Positive Data For Grass Sublingual Allergy Immunotherapy Tablet (RTTNews)
28.10.13	Merck Q3 Profit Falls, Adj. Earnings Top Estimates (RTTNews)
28.10.13	Pre-market Movers For Oct 28 (BIIB, MRK, MOS, BKW, DNDN, CLVS, SOHU, CYOU, SNTA) (RTTNews)
28.10.13	Merck Q3 Profit Declines,Yet Tops View; Narrows FY13 Adj. EPS View - Quick Facts (RTTNews)
28.10.13	Earnings Watch For October 28 (MRK, PMCS, STX, SANM, AAPL, PPS) (RTTNews)
23.10.13	Merck Gets Breakthrough Therapy Designation For MK-5172/MK-8742 (RTTNews)
15.10.13	Critical Alerts For Merck, 51Job, Comcast, Whole Foods, and FedEx Released By InvestorsObserver (PR Newswire)
15.10.13	Collaborations, Survey Results, Appointments, and Approvals - Research Report on Merck, Aetna, HCA, Medtronic, and Valeant Pharmaceuticals (PR Newswire)
04.10.13	Under AAAResearchReports.com Microscope: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. (PR Newswire)
04.10.13	Business Strategy, Partnerships, Presentation, and Appointment - Research Report on Merck, GSK, Sanofi, Intercept, and KYTHERA (PR Newswire)
01.10.13	Merck To Cut 8,500 Positions, Plans To Reduce $2.5 Bln Expenses By 2015 (RTTNews)
01.10.13	Pre-market Movers For Oct 1 (MRK, NFLX, LXRX, MYGN, WAG, OLED) (RTTNews)
01.10.13	Merck To Cut 8,500 Jobs; Backs FY13 Adj. EPS View - Quick Facts (RTTNews)
27.09.13	Updates on Pipeline Developments, Facility Expansions, and Conference Calls - Research Report on Merck, UnitedHealth, Amgen, Baxter, and Charles River (PR Newswire)
25.09.13	Dividends and Recognitions Affirming Strong Returns to Shareholders- Research Report on Merck, AbbVie, HealthSouth, Quintiles, and Ensign (PR Newswire)
25.09.13	Merck Agrees With FDA On Special Protocol Assessment For Tecemotide Trial (RTTNews)
24.09.13	Stock Movements, Quarterly Dividends and Product Recall News - Research Report on Pfizer, Johnson & Johnson, Bristol-Myers, Merck, and Abbvie (PR Newswire)
20.09.13	Issuer Ratings, Recognitions, Positive Clinical Results, and Quarterly Dividends - Research Report on Pfizer, UnitedHealth, Merck, Gilead, and Bristol-Myers (PR Newswire)
18.09.13	Clinical Trial Results, Licensing Agreements, Breakthrough Research and Development Programs - Research Report on Pfizer, Merck, Rockwell Medical, GlaxoSmithKline, and Novartis (PR Newswire)
17.09.13	NDA Updates, Signed Agreements, Awarded Patents, and Clinical Study Results - Research Report on Merck, Bristol-Myers Squibb, Amarin, GlaxoSmithKline, and Sanofi (PR Newswire)
16.09.13	New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline (PR Newswire)
11.09.13	Merck And AstraZeneca Announce Licensing Deal For Oral WEE1 Kinase Inhibitor (RTTNews)
10.09.13	Critical Alerts For Lowes, Merck, Express Scripts, VMware, and Level 3 Communications Released By InvestorsObserver (PR Newswire)
09.09.13	New Survey of People Living with HIV Shows Desire for Greater Doctor-Patient Dialogue about Treatment and Disease Impact (PR Newswire)
09.09.13	Merck: FDA Accepts NDA For Investigational Fertility Treatment - Quick Facts (RTTNews)
09.09.13	Event, FDA Approval, Positive Results, Partnership, and Marketing Authorization - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Lilly, and GSK (PR Newswire)
29.08.13	Early Briefing and Review: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. (PR Newswire)
17.08.13	Merck Temporarily Suspends Sales Of Zilmax (RTTNews)
12.08.13	Avanir Pharmaceuticals Inks Deal To Promote Merck's Januvia (RTTNews)
09.08.13	Critical Alerts For Disney, Merck, Whole Foods, Gilead Sciences, and Express Scripts Released By InvestorsObserver (PR Newswire)
06.08.13	Positive Opinions, Solid Margins, Agreements, and Clinical Trials to Boost Run Rate of Drug Manufacturers - Research Report on Johnson & Johnson, Pfizer, Merck, Bristol-Myers Squibb, and Lilly (PR Newswire)
31.07.13	Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint (PR Newswire)
30.07.13	Merck Profit Slides On Generic Competition For Singulair (RTTNews)
30.07.13	Merck & Co. Q2 Profit Beats Estimates - Quick Facts (RTTNews)
30.07.13	Earnings Watch For July 30 (SYMC, TTWO, JBLU, MRK, WU) (RTTNews)
26.07.13	Merck Says Confident In Safety Profile Of Sitagliptin - Quick Facts (RTTNews)
24.07.13	Technical Briefing: Pfizer, Merck & Co., AbbVie, and Zogenix (PR Newswire)
24.07.13	FDA Accepts Merck's NDA For Investigational Anti-thrombotic Drug Vorapaxar (RTTNews)
23.07.13	Drug Approvals, Study Results, and Clinical Collaborations for Top-Line Growth - Research Report on Pfizer, Merck & Co., Cubist, AstraZeneca and Impax (PR Newswire)
16.07.13	Merck Says FDA Panel Cancels Meeting On Sugammadex Sodium Injection (RTTNews)
04.11.09	Neuer Merck-Konzern nimmt Tätigkeit auf (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

09:18		Roche-Aktie dennoch leichter: CE-Kennzeichen für zwei Analysegeräte und EU-Zulassung für Vabysmo-Spritze
12.12.24		Dow Jones-Handel aktuell: Dow Jones beendet die Sitzung weit in der Verlustzone
12.12.24		Börse New York: Das macht der Dow Jones am Donnerstagmittag
12.12.24		Aufschläge in London: FTSE 100 legt zum Handelsende zu
12.12.24		Handel in Zürich: SMI letztendlich im Plus
12.12.24		SIX-Handel: SPI schlussendlich mit positivem Vorzeichen
12.12.24		Pluszeichen in New York: Anleger lassen Dow Jones zum Start des Donnerstagshandels steigen
12.12.24		Starker Wochentag in Frankfurt: LUS-DAX am Donnerstagnachmittag in der Gewinnzone

09:18

Roche-Aktie dennoch leichter: CE-Kennzeichen für zwei Analysegeräte und EU-Zulassung für Vabysmo-Spritze

12.12.24

Dow Jones-Handel aktuell: Dow Jones beendet die Sitzung weit in der Verlustzone

12.12.24

Börse New York: Das macht der Dow Jones am Donnerstagmittag

12.12.24

Aufschläge in London: FTSE 100 legt zum Handelsende zu

12.12.24

Handel in Zürich: SMI letztendlich im Plus

12.12.24

SIX-Handel: SPI schlussendlich mit positivem Vorzeichen

12.12.24

Pluszeichen in New York: Anleger lassen Dow Jones zum Start des Donnerstagshandels steigen

12.12.24

Starker Wochentag in Frankfurt: LUS-DAX am Donnerstagnachmittag in der Gewinnzone

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swiss Re	129.50	1.33 %	K V
Kuehne+Nagel Int	207.10	1.02 %	K V
Holcim	90.48	0.33 %	K V
Zurich Insur Gr	549.60	0.33 %	K V
Swiss Life Hldg	688.80	0.23 %	K V
Lonza Grp	546.60	-0.29 %	K V
Alcon	76.30	-0.34 %	K V
CieFinRichemont	135.00	-0.44 %	K V
Givaudan	4’021.00	-0.49 %	K V
Roche Hldg G	254.20	-0.51 %	K V

Nachrichten zu Merck Co.

Aktien Top/Flop

Merck Peer Group Nachrichten

Meistgelesene Nachrichten